Danielle Marcoux

ORCID: 0000-0003-2079-9166
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dermatology and Skin Diseases
  • Asthma and respiratory diseases
  • Food Allergy and Anaphylaxis Research
  • Allergic Rhinitis and Sensitization
  • Adrenal Hormones and Disorders
  • melanin and skin pigmentation
  • Psoriasis: Treatment and Pathogenesis
  • Autoimmune Bullous Skin Diseases
  • Genetic and rare skin diseases.
  • Nail Diseases and Treatments
  • Autoimmune and Inflammatory Disorders Research
  • Urticaria and Related Conditions
  • Skin Protection and Aging
  • RNA regulation and disease
  • Transgenic Plants and Applications
  • Cutaneous Melanoma Detection and Management
  • Chemotherapy-related skin toxicity
  • Acne and Rosacea Treatments and Effects
  • Body Image and Dysmorphia Studies
  • Cutaneous lymphoproliferative disorders research
  • Dermatological and Skeletal Disorders
  • Tattoo and Body Piercing Complications
  • Drug-Induced Adverse Reactions
  • Contact Dermatitis and Allergies
  • Parvovirus B19 Infection Studies

Université de Montréal
2015-2025

Centre Hospitalier Universitaire Sainte-Justine
2016-2025

Institute of Dermatology
2022

Odense University Hospital
2017

McGill University
2006-2013

Plastic Surgery Hospital
2013

Adult and Pediatric Dermatology
2013

University of Massachusetts Amherst
2010

General Department of Preventive Medicine
2008

National Institute of Allergy and Infectious Diseases
2008

Abstract: Molluscum contagiosum is a common viral disease of childhood presenting as small, firm, dome‐shaped umbilicated papules. Although benign and generally self‐limited, this condition contagious can lead to complications such inflammation, pruritus, dermatitis, bacterial superinfection, scars. No consensus has been established concerning the management condition. We conducted prospective randomized study comparing four treatments for molluscum in 124 children aged 1 18 years. One group...

10.1111/j.1525-1470.2006.00313.x article EN Pediatric Dermatology 2006-11-01

Abstract Therapeutic patient education ( TPE ) has proven effective in increasing treatment adherence and improving quality of life (QoL) for patients with numerous chronic diseases, especially atopic dermatitis AD ). This study was undertaken to identify worldwide experiences treatment. Experts from 23 hospitals, located 11 countries, responded a questionnaire on 10 major items. Patients programs were mainly children adolescents moderate severe or markedly affected QoL. Individual...

10.1111/pde.12024 article EN Pediatric Dermatology 2013-02-14

Linear morphoea (LM) is a rare fibrosing disorder of the limbs or face that may cause functional disability and severe aesthetic sequelae. Despite wide range therapeutics reported for LM, there currently lack consensus on optimal therapy. Little known about long-term outcome this disease.To describe short- large series patients with LM acquired in childhood.A retrospective chart review 52 paediatric seen our centre during 20-year span (1990-2010) telephone survey 2011 to assess these...

10.1111/bjd.12606 article EN British Journal of Dermatology 2013-09-06

Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their use. This study examined feasibility applying validated TOPICOP score assessing TCS phobia across different countries.This was a prospective multicentre conducted in 21 hospitals 17 countries. Patients >3 months age with or parents legal representatives completed translation questionnaire country's native language. Respondents also questionnaires...

10.1111/all.13189 article EN Allergy 2017-04-25

Abstract Poor adherence is frequent in patients with atopic dermatitis ( AD ), leading to therapeutic failure. Therapeutic patient education TPE ) helps chronic disease acquire or maintain the skills they need manage their disease. After a review of literature, group multispecialty physicians, nurses, psychologists, and worked together during two international workshops develop common recommendations for . These were structured as answers nine frequently asked questions about : What what are...

10.1111/pde.12045 article EN Pediatric Dermatology 2013-03-01

About 1% of children and adolescents worldwide are affected by plaque psoriasis.To evaluate the long-term efficacy safety ixekizumab for pediatric patients with moderate to severe psoriasis.This multicenter randomized clinical trial (IXORA-PEDS) evaluated psoriasis. Participants were aged 6 years younger than 18 years; had psoriasis, which was defined as Psoriasis Area Severity Index (PASI) 12 or higher, static Physician's Global Assessment (sPGA) score 3 psoriasis-affected body surface area...

10.1001/jamadermatol.2022.0655 article EN cc-by-nc-nd JAMA Dermatology 2022-04-13

10.1016/s0190-9622(96)90275-3 article EN Journal of the American Academy of Dermatology 1996-06-01

Abstract Atopic dermatitis (AD) is a disease that can have high impact on quality of life, especially due to itch and skin pain. This paper utilizes expertise from members the International Society Dermatitis (ISAD)/Oriented Patient‐Education Network in Dermatology (OPENED) task force review epidemiology, pathophysiology exacerbating factors pain atopic dermatitis. General principles treatment are provided, as well more detailed evaluation topical systemic therapies. Educational...

10.1111/jdv.16916 article EN Journal of the European Academy of Dermatology and Venereology 2020-10-08

ABSTRACT We report a patient with neuroichthyosis an ELOVL1 variant associated severe pruritus who responded well to dupilumab therapy. Our case is the third known reported this de novo heterozygous dominant variant. The feature of progressive greatly impairing quality life unique among these reports. After multiple treatment failures, he clinically and subjectively monoclonal antibody dupilumab.

10.1111/pde.15904 article EN cc-by-nc Pediatric Dermatology 2025-03-11

Adalimumab (ADA) (Humira® , AbbVie Inc., U.S.A.) is approved by the European Medicines Agency for children aged ≥ 4 years with severe plaque psoriasis.To evaluate long-term efficacy and safety of ADA in psoriasis.Results are presented from 52-week extension (LTE) randomized, double-blind, double-dummy, phase III trial, psoriasis (results prior periods have been published). Patients < 18 were randomized 1 : to 0·8 mg kg-1 (40 maximum) or 0·4 (20 every other week methotrexate (MTX) 0·1-0·4 (25...

10.1111/bjd.18029 article EN cc-by-nc-nd British Journal of Dermatology 2019-04-24

The arrival of biologics and small-molecule therapies (eg Janus kinase inhibitors) changed atopic dermatitis treatment, but older systemic treatments continue to be prescribed.

10.1016/j.jaad.2024.09.046 article EN cc-by Journal of the American Academy of Dermatology 2024-10-01

Background: Most people in the United States and Canada with pediculosis will be treated neurotoxic pediculicides containing pyrethrins or pyrethroids. Their widespread use led to significant resistance reported from various countries. Although treatment failures are frequently observed Canada, frequency pyrethroid pediculicide of human head lice (Pediculus humanus capitis) has not been determined. Objective: To determine knockdown ( kdr) allele louse populations Canada. Methods: Patients...

10.2310/7750.2010.09032 article EN Journal of Cutaneous Medicine and Surgery 2010-05-01
Coming Soon ...